Research Papers:

Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon

Yi-Dong Hong, Jian Zhang, Ming Zhuang, Wei Li, Puy-Uan Wu, Ru-Tian Li, Nan Hu, Bao-Xiang Bian, Zi-Yan Song and Feng-Lei Wu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:114495-114505. https://doi.org/10.18632/oncotarget.21274

Metrics: PDF 2299 views  |   HTML 2686 views  |   ?  


Yi-Dong Hong1,2,*, Jian Zhang3,*, Ming Zhuang1,*, Wei Li4, Puy-Uan Wu5, Ru-Tian Li5, Nan Hu1, Bao-Xiang Bian1, Zi-Yan Song1 and Feng-Lei Wu1

1Department of Oncology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, 221002, China

2Deparment of Oncology, School of Medicine, Jiangsu University, Zhengjiang, Jiangsu, 212013, China

3Department of General Surgery, Huai'an First People's Hospital, Nanjing Medical University, Huai’an, Jiangsu, 223000, China

4Center of Research Laboratory, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, 222000, China

5The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, China

*Co-first authors

Correspondence to:

Feng-Lei Wu, email: [email protected]

Keywords: TFAP2E, hypermethylation, epigenetic drugs, nanoparticles, drug delivery

Received: May 27, 2017     Accepted: September 08, 2017     Published: September 26, 2017


Hypermethylation of the transcription factor AP-2 epsilon (TFAP2E) gene affects 5-fluorouridine (5-FU) resistance in gastric cancer (GC) patients. The epigenetic inhibitor 5-Aza-2’-deoxycytidine (DAC), which reverses DNA methylation by targeting DNA methyltransferases (DNMTs), has potential to sensitize GC to 5-FU. Nevertheless, DNA demethylation only DAC transiently occurs since DAC is unstable in aqueous solutions, which limits its potential. Here we developed intelligent nanoparticles (NPs) comprising gelatinase with polyethylene glycol (PEG) and poly-ε-caprolactone) (PCL) to specifically deliver DAC (DAC-TNPs) to tumors. DAC-carrying PEG-PCL NPs (DAC-NPs) lacking gelatinase features served as controls. 72 hours after administration of DAC-TNPs or DAC-NPs, 5-FU was sequentially applied to GC cells and human GC xenografts in nude mice. Both in vitro and in vivo evaluations demonstrated that the combination treatment of DAC-TNPs and 5-FU greatly improved tumor suppression in GC cells and mouse xenograft models with hypermethylation TFAP2E (MKN45 cells). We thus propose that the sequential administration of DAC-TNPs and 5-FU could be significant in the development of novel targeted therapies.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21274